Literature DB >> 20045804

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.

Luis V Syro1, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Eva Horvath, Fabio Rotondo, Kalman Kovacs.   

Abstract

The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH. Immunohistochemistry for O6 Methylguanine-DNA Methyl-Transferase (MGMT) showed an admixture of immunopositive and immunonegative cells. After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug. Following Temozolomide administration the MRI demonstrated significant tumor necrosis. A few months later, the patient died of massive pulmonary embolism. No autopsy was performed. The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045804     DOI: 10.14310/horm.2002.1247

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  14 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

3.  MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

Authors:  George Kontogeorgos; Eleni Thodou; Mary Koutourousiou; Gregory Kaltsas; Andreas Seretis
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 4.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

5.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

6.  Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports.

Authors:  Yan Ji; Rachel Isaksson Vogel; Emil Lou
Journal:  Neurooncol Pract       Date:  2015-11-12

7.  Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.

Authors:  Emilie Morin; France Berthelet; John Weisnagel; Martin Bidlingmaier; Omar Serri
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 8.  Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.

Authors:  Ali A Ghazi; Fabio Rotondo; Kalman Kovacs; Alireza Amirbaigloo; Luis V Syro; Hussein Fathalla; Antonio Di Ieva; Michael D Cusimano
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

9.  Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.

Authors:  Fateme Salehi; Bernd W Scheithauer; Veronica J Moyes; William M Drake; Luis V Syro; Branavan Manoranjan; Soniya Sharma; Eva Horvath; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2010-12       Impact factor: 3.943

Review 10.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.